BioVector? 阿爾茨海默癥病人來(lái)源 iPSC 細(xì)胞株 / BioVector? Alzheimer’s Disease Patient-Derived iPSC Lines

通用定義 / General Definition:

BioVector? 阿爾茨海默癥 (AD) 病人來(lái)源的誘導(dǎo)多能干細(xì)胞 (iPSC) 是通過(guò)重新編程 AD 患者的體細(xì)胞（如皮膚成纖維細(xì)胞或外周血單核細(xì)胞）而建立的。這些細(xì)胞株攜帶患者特有的遺傳背景，包括與家族性 AD (fAD) 相關(guān)的基因突變（如 APP、PSEN1、PSEN2）或與散發(fā)性 AD (sAD) 相關(guān)的風(fēng)險(xiǎn)等位基因（如 APOE4）。這些 iPSC 可以分化為神經(jīng)元、星形膠質(zhì)細(xì)胞和微膠質(zhì)細(xì)胞，是研究 AD 發(fā)病機(jī)制、淀粉樣蛋白 ($A\beta$) 沉積、Tau 蛋白過(guò)度磷酸化以及進(jìn)行精準(zhǔn)藥物篩選的革命性人源模型。

BioVector? Alzheimer’s Disease (AD) patient-derived Induced Pluripotent Stem Cells (iPSCs) are established by reprogramming somatic cells (e.g., skin fibroblasts or PBMCs) from AD patients. These lines retain the patient’s specific genetic landscape, including mutations associated with familial AD (fAD) such as APP, PSEN1, or PSEN2, as well as risk alleles for sporadic AD (sAD) like APOE4. These iPSCs can be differentiated into neurons, astrocytes, and microglia, serving as a revolutionary human-based model for studying AD pathogenesis, amyloid-beta ($A\beta$) deposition, Tau hyperphosphorylation, and precision drug screening.

BioVector? AD-iPSC 技術(shù)說(shuō)明書(shū) (Technical Datasheet)

中文版說(shuō)明書(shū) (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? AD 病人來(lái)源 iPSC 細(xì)胞株

• 遺傳背景： 提供多種亞型（如 PSEN1 $\Delta$E9, APP Swedish 突變, 或 APOE4/4 純合子）。

• 重編程方式： 非整合型（如塞內(nèi)卡病毒或游離質(zhì)粒），確?；蚪M穩(wěn)定性。

• 多能性驗(yàn)證： 表達(dá) OCT4, NANOG, SOX2, SSEA4 等標(biāo)志物；具有三胚層分化能力。

• 生長(zhǎng)特性： 貼壁生長(zhǎng)（需包被基質(zhì)膠）。

2. 培養(yǎng)與分化條件

• 維持培養(yǎng)基： BioVector? mTeSR Plus 或 Essential 8 無(wú)血清培養(yǎng)基。

• 包被要求： 使用 Matrigel 或 Laminin-511 進(jìn)行預(yù)包被。

• 分化方向： * 皮層神經(jīng)元： 通過(guò)雙 SMAD 抑制法誘導(dǎo)。

  • 小膠質(zhì)細(xì)胞： 通過(guò)造血前體細(xì)胞階段誘導(dǎo)。

• 培養(yǎng)環(huán)境： 37 攝氏度，5% $CO_2$。

3. 細(xì)胞應(yīng)用

• 病理機(jī)制研究： 觀察患者神經(jīng)元中的 $A\beta_{42}/A\beta_{40}$ 比例升高及突觸丟失。

• Tau 病變模擬： 誘導(dǎo)形成神經(jīng)原纖維纏結(jié)并研究 Tau 蛋白的錯(cuò)誤折疊。

• 高通量篩選： 利用人源背景篩選能降低 $A\beta$ 毒性或改善線粒體功能的化合物。

4. 注意事項(xiàng)

• 基因組完整性： iPSC 在長(zhǎng)期傳代過(guò)程中可能發(fā)生核型改變，建議每 10-15 代進(jìn)行一次核型分析。

• 等基因?qū)φ?(Isogenic Control)： 為了嚴(yán)格證明表型由特定突變引起，BioVector? 建議搭配使用經(jīng) CRISPR/Cas9 修復(fù)的等基因?qū)φ罩辍?/p>

English Datasheet

1. General Product Information

• Product Name: BioVector? AD Patient-Derived iPSC Lines

• Genetic Background: Various subtypes available (e.g., PSEN1 $\Delta$E9, APP Swedish mutation, or APOE4/4 homozygotes).

• Reprogramming Method: Non-integrative (e.g., Sendai virus or Episomal vectors) to ensure genomic integrity.

• Pluripotency Validation: Confirmed expression of OCT4, NANOG, SOX2, and SSEA4; demonstrated tri-lineage differentiation potential.

• Growth Properties: Adherent (requires basement membrane matrix coating).

2. Culture and Differentiation Conditions

• Maintenance Medium: BioVector? mTeSR Plus or Essential 8 Serum-Free Medium.

• Surface Coating: Plates must be pre-coated with Matrigel or Laminin-511.

• Differentiation Lineages:

  • Cortical Neurons: Induced via dual-SMAD inhibition.

  • Microglia: Induced via a hematopoietic progenitor intermediate stage.

• Incubation: 37 degrees Celsius, 5% $CO_2$.

3. Applications

• Pathogenesis Research: Observing elevated $A\beta_{42}/A\beta_{40}$ ratios and synaptic loss in patient-specific neurons.

• Tauopathy Modeling: Inducing neurofibrillary tangle formation and studying Tau misfolding mechanisms.

• High-Throughput Screening: Screening for compounds that reduce $A\beta$ toxicity or improve mitochondrial function in a human genetic context.

4. Key Usage Notes

• Karyotypic Stability: iPSCs may undergo genomic alterations during extended culture; BioVector? recommends karyotyping every 10–15 passages.

• Isogenic Controls: To definitively link phenotypes to specific mutations, BioVector? strongly advises the use of CRISPR/Cas9-corrected isogenic control lines.

注意 / Note: BioVector? AD-iPSC 應(yīng)在生物安全二級(jí) (BSL-2) 條件下操作。由于這些細(xì)胞株具有無(wú)限增殖潛力及特定的疾病表型，在研究中需特別關(guān)注培養(yǎng)環(huán)境的穩(wěn)定性以防止自發(fā)分化。

BioVector? AD-iPSCs should be handled under Biosafety Level 2 (BSL-2) conditions. Due to their infinite self-renewal potential and disease-specific phenotypes, maintaining a stable culture environment is critical to prevent spontaneous differentiation.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

E-mail: [email protected]

http://www.nedfriskphoto.com